Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01492088 · ClinicalTrials.gov registry record · Phase 1

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

A Phase 1 study of Relapsed or Refractory Hodgkin Lymphoma and Relapsed or Refractory Anaplastic Large-cell Lymphoma, sponsored by Millennium Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
36
Enrollment target
18
Study locations

NCT01492088 is a Phase 1 study of Relapsed or Refractory Hodgkin Lymphoma and Relapsed or Refractory Anaplastic Large-cell Lymphoma that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 36 participants. The trial reports 18 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01492088, a Phase 1 study of Relapsed or Refractory Hodgkin Lymphoma and Relapsed or Refractory Anaplastic Large-cell Lymphoma, has completed, sponsored by Millennium Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
36 participants
Enrollment target
18
Study locations

Study Summary

The purpose of this study is to assess the safety and pharmacokinetics, and determine the pediatric maximum tolerated dose and/or or recommended phase 2 dose of brentuximab vedotin.

Conditions Studied

Relapsed or Refractory Hodgkin Lymphoma Relapsed or Refractory Anaplastic Large-cell Lymphoma

Interventions

  • DRUG Brentuximab vedotin

Study Locations (18)

Other

  • - Bordeaux
  • - Lyon
  • - Paris
  • - Berlin
  • - Frankfurt
  • - Giessen
  • - Halle
  • - Münster
  • - Padua
  • - Roma
  • - Mexico City
  • - Rotterdam
  • - Barcelona
  • - London

Colorado

  • - Aurora

Missouri

  • - Kansas City

New York

  • - New York

Texas

  • - Houston

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2012-04-16
Est. Completion 2018-04-12
Phase Phase 1

Sponsor

Millennium Pharmaceuticals

135 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01492088

The ClinicalTrials.gov registry entry for NCT01492088 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Relapsed or Refractory Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Brentuximab vedotin is the first listed.

NCT01492088 reports 18 study locations spanning 5 distinct geographic areas - top geographies include Other, Colorado, Missouri.

Frequently Asked Questions

What is clinical trial NCT01492088 about?

NCT01492088 is a clinical study titled "Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma". The purpose of this study is to assess the safety and pharmacokinetics, and determine the pediatric maximum tolerated dose and/or or recommended phase 2 dose of brentuximab vedotin.

What is the current status of trial NCT01492088?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2012-04-16. Estimated completion is 2018-04-12.

What conditions does trial NCT01492088 study?

This clinical trial studies the following conditions: Relapsed or Refractory Hodgkin Lymphoma, Relapsed or Refractory Anaplastic Large-cell Lymphoma.

What interventions are being tested in trial NCT01492088?

The interventions under investigation include: Brentuximab vedotin (DRUG).

Who is sponsoring clinical trial NCT01492088?

This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01492088 being conducted?

This trial has 18 study locations across Colorado, Missouri, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Relapsed or Refractory Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Relapsed or Refractory Hodgkin Lymphoma

All registered trials for this condition

Relapsed or Refractory Anaplastic Large-cell Lymphoma

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.